HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non–small cell lung cancer

HDAC3 is one of the main targets of histone deacetylase (HDAC) inhibitors in clinical development as cancer therapies, yet the in vivo role of HDAC3 in solid tumors is unknown. We identified a critical role for HDAC3 in Kras-mutant lung cancer. Using genetically engineered mouse models (GEMMs), we f...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichner, Lillian J., Curtis, Stephanie D., Brun, Sonja N., McGuire, Caroline K., Gushterova, Irena, Baumgart, Joshua T., Trefts, Elijah, Ross, Debbie S., Rymoff, Tammy J., Shaw, Reuben J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022903/
https://www.ncbi.nlm.nih.gov/pubmed/36930718
http://dx.doi.org/10.1126/sciadv.add3243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022903/
https://www.ncbi.nlm.nih.gov/pubmed/36930718
http://dx.doi.org/10.1126/sciadv.add3243

Ejemplares similares